In Haemostasis, 
There’s routine... and then there’s Routine

With Stago, discover an outstanding Routine range
More than 80% of tests performed in Haemostasis laboratories are routine tests.

We are committed to supporting you in your daily practice by offering you the most effective product range.

In laboratory medicine, it is essential that test results are reliable and reproducible.

Through its R&D programmes and its continuous improvement process, Stago strives to offer the most effective, standardised reagents, suited to the laboratory’s workload.

An optimal “Routine” range for guaranteed satisfaction

1. Comprehensive range
   Stago’s extensive panel of reagents meets the needs of any laboratory, whatever its clinical setting or workload:
   - wide choice of thromboplastins and cephalins
   - many assayed quality control plasmas

2. Robust reagents
   Stago’s Routine Range offers excellent analytical performance characteristics to ensure reliable patient results:
   - wide working ranges
   - excellent precision and accuracy
   - appropriate sensitivity

3. Convenient products
   Reagents must be simple and easy to use in order to optimise productivity and reduce the risk of error. Stago is developing a range of systems to meet your expectations:
   - many ready-to-use liquid reagents
   - systematically barcoded for ergonomic workflows and maximum traceability (automated management of batch numbers, volumes, stability data and expiry dates, precalibration, etc.)

4. Cost-effectiveness
   Choose the best pack size/stability combination to optimise reagent use based on your laboratory’s workload. Stago helps you to cope with economic constraints by providing the most suitable solution:
   - more than ten pack sizes available
   - extended stability both on-board and at 2–8°C

5. Standardisation
   For patient monitoring, it is crucial that results are standardised across laboratories. Stago offers various solutions to help achieve this:
   - instrument-specific ISI* values for analysers of the STA® range
   - precalibrated reagents
   - calibrators and controls assayed against international standards
   - control ranges validated on all analysers of the STA® range
   - excellent batch-to-batch reproducibility

*International Sensitivity Index

Stago, your laboratory’s Haemostasis Partner
PT tests account for more than 50% of the coagulation tests performed worldwide.

The clinical impact of PT testing is significant: laboratories therefore need an appropriate, robust reagent in order to obtain reliable results.

**Broad range of thromboplastins to accommodate local practices**
- Quick and Owren method
- animal or recombinant human thromboplastins
- wide choice of ISI values (0.9–1.8)

**Reliable patient results**
- excellent sensitivity to factor deficiencies
- no interference from unfractionated heparins (UFH) or low molecular weight heparins (LMWH) at therapeutic doses
- reduced sensitivity to Lupus Anticoagulants (LA)

**Standardised results for reliable diagnosis**
- precalibrated reagents
- instrument-specific ISI values, assayed against international standards
- excellent batch-to-batch reproducibility

Maximum convenience for a routine test
- barcoded reagents
- range of pack sizes (5, 10 and 15 mL)
- easy to reconstitute, no pipetting required
- extended stability for 24/7 availability

To comply with regulatory requirements, laboratories must perform regular internal quality control (IQC) on at least two concentration levels (normal and abnormal) to check and confirm the performance of their testing systems.

**To ensure the reliability of patient results**
- evaluation of the precision and accuracy of the reagent-analyser combination
- several concentration levels reflecting most clinical scenarios (normal, abnormal, and severely abnormal)

Wide choice of IQC plasmas to suit any workload, in order to optimise your operating budget
- different pack sizes available (1 or 2 mL) to enable several series of IQC tests to be performed every day
- optimal on-board stability: 8 to 24 hours
Choosing an APTT reagent is a real challenge for laboratories: they must find the right compromise between the nature of their workload and the sensitivity of the reagent.

When the nature of the laboratory’s workload is varied — preoperative screening, monitoring of UFH therapy, detection of LA — an “all-purpose” reagent is required, which has optimum sensitivity to factor deficiencies, UFH therapy(1) and LA.

### STA®-PTT A

Wide choice of cephalins and activators for a “customised” reagent
- animal cephalins
- various activators (kaolin, silica, polyphenolic activator)

Ergonomic workflows
- ready-to-use liquid reagents
- extended stability, adapted to any workload

### STA®-Cephascreen® / STA®-C.K. Prest®

The aim of a preoperative screening is to identify the patient’s bleeding risk.
The reagent used must have optimum sensitivity to factor deficiencies and low sensitivity to transient circulating anticoagulants.

### Controls

Assayed multiparameter IQC reagents
- ranges validated on every analyser of the STA® range
- assayed against international standards

A key component of your system thanks to automated, barcode-based management of product data
- automatic allocation of dedicated ranges
- management of volumes, stability, expiry dates, batch numbers, etc.
There are numerous considerations for the determination of fibrinogen in routine laboratory testing. Stago’s innovative new reagent combines convenience and robustness:

**STA®-Liquid Fib**

**Test based on the “gold standard” method, for maximum reliability**
- **Clauss** method
- extremely reliable patient results across a large measuring range

**Benefits of mechanical detection**
- better reproducibility than photo-optical detection in fibrinogen assays (1)
- insensitive to sample turbidity following massive transfusion (2,3)
- no interference from lipaemia, icterus or haemolysis (4)

**Superior analytical performance characteristics**
- wide working range: 0.4–12 g/L, covers any clinical situation
- excellent precision

<table>
<thead>
<tr>
<th>Sample</th>
<th>Intra assay reproducibility</th>
<th>Inter assay reproducibility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>X (g/L)</td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>2.83</td>
</tr>
<tr>
<td>n</td>
<td>21</td>
<td>1.03</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>2.84</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>1.03</td>
</tr>
<tr>
<td>SD (g/L)</td>
<td>0.06</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>CV (%)</td>
<td>2.1</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>2.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.2</td>
<td></td>
</tr>
</tbody>
</table>

**Correlates perfectly with STA®-Fibrinogen 5(A) and STA®-Fib 2(B)**

Graph A

Graph B

A reagent that makes life easier: your results are available in less than 5 minutes
- ready-to-use liquid reagent
- precalibrated and barcoded

An economical solution adapted to any workload through optimised reagent management
- a single 4-mL format
- extended stability: 10 days on-board; 2 months at 2–8°C

---

(2) Guidelines on fibrinogen assays. BJH, 2003, 121, 396-404
(3) Adam S. et al. Photo-Optical methods can lead to clinically relevant overestimation of fibrinogen concentration in plasma diluted with Hydroxyethyl Starch. Clinical and Applied Thrombosis/Haemostasis vol 16 number 1 July/August 2010 461-471
**PT**

<table>
<thead>
<tr>
<th></th>
<th>STA®-Néoplastine® R</th>
<th>STA®-Néoplastine®CI Plus</th>
<th>STA®-Néoplastine® CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thromboplastin origin</td>
<td>Recombinant</td>
<td>Extraction</td>
<td></td>
</tr>
<tr>
<td>ISI</td>
<td>0.9 - 1.1</td>
<td>1.1 - 1.3</td>
<td>1.6 - 1.8</td>
</tr>
<tr>
<td>Heparin sensitivity</td>
<td>UFH: 1.0 UI/mL</td>
<td>LMWH: 2.0 UI/mL</td>
<td>UFH: 1.0 UI/mL</td>
</tr>
<tr>
<td>On-board stability</td>
<td>5 days</td>
<td>48 / 96 h</td>
<td></td>
</tr>
<tr>
<td>Cat. Nr./Packaging</td>
<td>00665 – 12 x 15 mL</td>
<td>00606 – 6 x 5 mL</td>
<td>00605 – 6 x 5 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00667 – 12 x 10 mL</td>
<td>00666 – 12 x 10 mL</td>
</tr>
</tbody>
</table>

* on STA Satellite®

**APTT**

<table>
<thead>
<tr>
<th></th>
<th>STA®-C.K. Prest®</th>
<th>STA®-Cephascreen®</th>
<th>STA®-PTT A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activator</td>
<td>kaolin</td>
<td>polyphenol</td>
<td>silica</td>
</tr>
<tr>
<td>Format</td>
<td>lyophilised</td>
<td>liquid</td>
<td>lyophilised</td>
</tr>
<tr>
<td>On-board stability</td>
<td>24 / 48 h</td>
<td>00308: 7 / 8’ days</td>
<td>24 h</td>
</tr>
<tr>
<td>Cat. Nr./Packaging</td>
<td>00597 – 6 x 5 mL</td>
<td>00308 – 12 x 4 mL</td>
<td>00595 – 12 x 5 mL</td>
</tr>
</tbody>
</table>

* on STA Satellite®; ** on STA Compact Max®

**Fibrinogen**

<table>
<thead>
<tr>
<th></th>
<th>STA®-Liquid Fib</th>
<th>STA®-Fibrinogen 5</th>
<th>STA®-Fib 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Format</td>
<td>Liquid</td>
<td>Lyophilised</td>
<td>Lyophilised</td>
</tr>
<tr>
<td>Measuring range</td>
<td>1 - 8 default dilution</td>
<td>1.5 - 9</td>
<td>1.5 - 8</td>
</tr>
<tr>
<td>- With automatic re-dilutions</td>
<td>0.4 - 12</td>
<td>0.6 - 12</td>
<td>0.6 - 12</td>
</tr>
<tr>
<td>On-board stability</td>
<td>10 days</td>
<td>5 / 8’ days</td>
<td>4 / 8’ days</td>
</tr>
<tr>
<td>Stability at 2-8°C</td>
<td>60 days</td>
<td>14 days</td>
<td>14 days</td>
</tr>
<tr>
<td>Cat. Nr./Packaging</td>
<td>00673 – 12 x 4 mL</td>
<td>00674 – 12 x 5 mL</td>
<td>00238 – 6 x 2 mL</td>
</tr>
</tbody>
</table>

* on STA Satellite®

**Quality Controls**

<table>
<thead>
<tr>
<th></th>
<th>STA®-Routine QC 2 mL</th>
<th>STA®-Routine QC P Plus</th>
<th>STA®-Coag Control (N + ABN) Plus</th>
<th>STA®-Coag Control N+P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levels</td>
<td>STA® Routine QC 2 mL N</td>
<td>STA® Routine QC 2 mL P</td>
<td>STA® Coag Control N Plus</td>
<td>STA® Coag Control N Plus</td>
</tr>
<tr>
<td></td>
<td>STA® Routine QC 2 mL P</td>
<td>STA® Coag Control P Plus</td>
<td>STA® Coag Control N Plus</td>
<td>STA® Coag Control P</td>
</tr>
<tr>
<td>Parameters</td>
<td>PT (Sec, % and INR) Owren’s PT (%), INR</td>
<td>APTT</td>
<td>Fibrinogen</td>
<td>Thrombin time (N)</td>
</tr>
<tr>
<td></td>
<td>PT (Sec, %) APTT</td>
<td>Fibrinogen</td>
<td>Thrombin time</td>
<td>Antithrombin (%)</td>
</tr>
<tr>
<td></td>
<td>PT (Sec, %) APTT</td>
<td>Fibrinogen</td>
<td>Thrombin time</td>
<td>Antithrombin (%)</td>
</tr>
<tr>
<td></td>
<td>PT (Sec, %) APTT</td>
<td>Fibrinogen</td>
<td>Thrombin time</td>
<td>Antithrombin (%)</td>
</tr>
<tr>
<td>On-board stability</td>
<td>24 h</td>
<td>24 h</td>
<td>24 h</td>
<td>8 h</td>
</tr>
<tr>
<td>Cat. Nr./Packaging</td>
<td>00554 – 12 x 2 x 2 mL</td>
<td>00714 – 24 x 1 x 2 mL</td>
<td>00677 – 12 x 2 x 2 mL</td>
<td>00679 – 12 x 2 x 1 mL</td>
</tr>
</tbody>
</table>

*For United Kingdom only

For further information, please contact: